Olanzapine/samidorphan

Drug Profile

Olanzapine/samidorphan

Alternative Names: ALKS 33/olanzapine; ALKS-3831; Olanzapine/ALKS 33; Samidorphan/olanzapine

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alkermes plc
  • Class Amides; Antipsychotics; Benzodiazepines; Oxazepines; Small molecules; Thiazepines
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Opioid mu receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bipolar disorders; Psychotic disorders; Schizophrenia

Most Recent Events

  • 20 Jul 2017 Alkermes completes a phase I pharmacodynamics trial in Healthy volunteers in USA (PO, Tablet) (NCT02922426)
  • 29 Jun 2017 Top-line efficacy and adverse events data from the phase III ENLIGHTEN-1 trial for Schizophrenia released by Alkermes
  • 08 Jun 2017 Phase-III clinical trials in Bipolar disorders and Psychotic disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top